2. Select the new

4. Rightclick on picture,

An Introduction to Danish Life Science

- and Medicon Valley

Bangalore INDIA BIO 2011

AGENDA

3 August, 2011

BIOTECH IN DENMARK

MEDICON VALLEY

Denmark & Medicon valley

3 August, 2011

The Danish Life Sciences Cluster - facts

- 25 CROs

- ≥ 160 core biotech

companies

- ≥ 180 core medtech

companies

- 48,000 employees in the life

science industry

- 7 science parks

- 8 universities

- 75 hospitals (4 major university

hospitals)

- 10,000 life science graduates

annually

- 2,000 LS PhDs students

graduating annually

BIOTECH IN DENMARK

DENMARK COMPARES WELLand it is not just something we say...

• Denmark is among the five countries in the world (and 2nd

in Europe) with the most likely potential for development

of biotechnology(Scientific American 2010)

• The 3rd best overall biotech sector in the world(fDi Magazine, 2008)

• Stable funding situation in the middle of a financial storm(Ernst and Young 2010)

• The 3rd largest commercial drug development pipeline in

Europe (in actual numbers)(Ernst and Young 2010)

BIOTECH IN DENMARK

6

Denmark – European TOP 3 position (pipeline)

Source: Ernst & Young, Beyond borders 2010

Preclinical:

69Phase I:

59Phase II:

58Phase III:

40

(Total commercial drug development pipeline in Denmark Source: Invest

in Denmark, 2010; Copenhagen Capacity 2010)

Research

BIOTECH IN DENMARK

7

THE POOL OF BIOTECH´S KEEPS GROWING

0

2

4

6

8

10

12

14

16

18

20

until 1

925

1925-1

950

1951-1

975

1976-1

985

1986-1

990

1991-1

995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

Anta

l sta

rt-u

ps

New Biotech Start-ups in Denmark

Source: Danish Biotech Ass., December 2009

BIOTECH IN DENMARK

8

TOTAL NUMBER OF BIOTECH COMPANIES IN DENMARK

0

20

40

60

80

100

120

140

160

180

Indtil …

1988

1989

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

Anta

l vir

ksom

heder

Source: Danish Biotech Ass., December 2009

BIOTECH IN DENMARK

0

10

20

30

40

50

60

1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

Bill

ion

DK

K

Denmark is among the largest exporters per capita of pharmaceutical products

Development in Danish drug exports 1997-2010:

BIOTECH IN DENMARK

THE DANISH LIFE SCIENCE CLUSTER HOLDS AREAS OF

GLOBAL BUSINESS EXCELLENCE & STRONGHOLDS

ICTBIOTECH MEDTECH

ROBOTICS

HEALTHCARE IT

CANCER

METABOLIC

CNS

DIAGNOSTICS

ASSITIVE TECHNOLOGY

DISPOSABLES

INVEST IN DENMARK

INFLAMATORY & INFECTION DISEASES

Danish competences – Biotech cluster

Areas of Business Excellences

- Cancer/oncology

- CNS/Neuroscience

- Metabolic diseases

- Inflammatory and Infectious diseases

Biotech strongholds

(Technological platforms)

- Biomedical Informatics

- Clinical Trials

- Personalized Medicine

- Proteomics

- Nanomedicine

- Drug Delivery

- Vaccines

BIOTECH IN DENMARK

Life Science centres in Denmark

Science Parks

Innovation Incubators

University Hospitals

BIOTECH IN DENMARK

7 Science Parks

The Science Parks holds:

• Incubator solutions

• Access to VC’s- from pre-seed to seed

• A facilitating and knowledge-sharing

environment

• Access to state-of-the-art lab facilities

• Cost-competitive m2 prices

• Usually located close to the universities

6 Innovation Incubators

Innovation incubators:

• seeks out and screen risky commercialization ideas

invest in commercialization ideas

• ensure access to appropriate facilities for the knowledge-based

entrepreneurship

• advise entrepreneurs on how to maturation the commercializing idea

• help entrepreneurs to build contacts with private investors to attracted

capital

The purpose of the innovation incubator scheme is to create and develop more knowledge-intensive start-ups with unique skills

CLUSTERS IN DENMARK Northern Jutland/Aalborg

• Biomedical technology

Central Jutland/Aarhus

• Biotech/Biomedical

technology/Food

innovation

Funen/Odense

• Biomedical technology

Copenhagen area

• Medicon Valley

BIOTECH IN DENMARK

MEDICON VALLEY

MEDICON VALLEY

MEDICON VALLEY – one of Europe´s strongest life science clusters

1997 2011

MEDICON VALLEY

18

MEDICON VALLEY – BASIC FACTS & FIGURES

Population: 3.5 mill.

7 large R&D based

pharma companies with

local roots

App.150 biotechs with

own R&D

App. 200 medtech

companies

More than 50 CROs and

CMOs

33 hospitals (of which 11

are university hospitals)

44.000 life-science

employees in the private

sector

9 science parks

11 universities (5 supply

life science educations)

155.000 students (app

1/3 in Life Sciences)

More than a dozen VCs

with experienced life

science teams

MEDICON VALLEY

MEDICON VALLEY STRONGHOLDS

• Global leadership in diabetes and

obesity

• World-class R&D in CNS

• Very strong R&D tradition in other

important therapeutic areas, e.g.

inflammation, infectious diseases,

immunology and oncology

• Emerging position in the field of

personalized medicine

MEDICON VALLEY

MEDICON VALLEY – where tradition meets the future

Tradition: Novo Nordisk, LEO

Pharma, Lundbeck, Nycomed,

Ferring, ALK Albello

Stars of the future: Bavarian

Nordic, Neurosearch, Zealand

Pharma, Genmab, Santaris

Pharma, Symphogen, Lifecycle

Pharma, Action Pharma, Exiqon

MEDICON VALLEY

www.mediconvalley.com

Danish headline deal makers (selected examples)

• Topotarget and Spectrum Pharmaceuticals (2010)• Genmab : GSK (2006) and TenX (2010)• LEO : Buy-back of US psoriasis portfolio from Warner-Chilcott (2009)• LEO : Acquisition of Peplin (AU) for USD 287.5 mill. (2009)• Santaris: Enzon (2006), GSK (2007), Wyeth (2009) and Shire (2009)• Neurosearch: Abbot (1999), GSK (2003) and Eli Lilly (2009), Janssen

(2009)• Symphogen: Meiji Seika (2006), Genentech (2008), Origen (2009)• Upfront Chromatography and Cangene (2009)• Egalet and RedHill Biopharma (2009)• Nuevolution: Merck(2008)• Lundbeck: Ovation acquisition (2008)• Zealand: Sanofi-Aventis (2003) and Helsinn (2008)• Zymenex : Divestment of Metazym to Shire (2008) • Exiqon: OncoTech acquisition (2007) • Lifecycle : Mylan (2006), Sandoz (2006) and Sciele (2007)

BIOTECH IN DENMARK

Business Solutions

Choose DK for your next R&D Center

Choose DK for your Sales\Marketing office

Choose DK for Biopharmaceutical Production

Choose DK for your North European HQ

The Best Environment for conducting Clinical Trials

BIOTECH IN DENMARK

Denmark’s best business framework

• Flexicurity – easy hire and lay off practices

• Best labour relations in the world

• Human resources - World’s most motivated and best trained labour force

• Flexible and cooperative government – no red tape

• 2nd most stable political environment in the world

• 25% corporate tax

• 3rd best infrastructure in the world

• Economic top performer

BIOTECH IN DENMARK

Assistance from INVEST IN DENMARK

• Identification of specific business opportunities

Potential partners

• Comprehensive fact base and decision-making support

Taxation, employment laws, regulatory issues

• Local contacts

IP consultants, lawyers, authorities & public/private

co-operation partners

• Tools – unique benchmark, cost/benefit & logistic tools

BIOTECH IN DENMARK

For more information , Pls contact below :

INVEST IN DENMARK– INDIA OFFICE

M +91 99456 96801

DIR: 91 80 4157 0057

EMAIL PRADAS@UM.DK

TRADE COMMISSION OF DENMARK

142, 4th Main Road, Defence Colony

Indiranagar, BANGALORE - 560 038

Tel: +91 (80) 4157 0057

WWW.INVESTINDK.COM

PRAMILA DAS , MSc, MBAInvestment Manager, LifeSciences